Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 1
2009 3
2010 7
2011 5
2012 7
2013 13
2014 6
2015 3
2016 3
2017 5
2018 4
2019 4
2020 9
2021 12
2022 16
2023 18
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

109 results

Results by year

Filters applied: . Clear all
Page 1
In vitro activity of cefiderocol against European Pseudomonas aeruginosa and Acinetobacter spp., including isolates resistant to meropenem and recent β-lactam/β-lactamase inhibitor combinations.
Santerre Henriksen A, Jeannot K, Oliver A, Perry JD, Pletz MW, Stefani S, Morrissey I, Longshaw C; ARTEMIS Study Investigators. Santerre Henriksen A, et al. Microbiol Spectr. 2024 Apr 2;12(4):e0383623. doi: 10.1128/spectrum.03836-23. Epub 2024 Mar 14. Microbiol Spectr. 2024. PMID: 38483164 Free article.
Novel CMY-186 variant conferring cross-resistance to cefiderocol and ceftazidime/avibactam in Klebsiella pneumoniae from a critically ill patient during cefiderocol and ceftazidime/avibactam treatment.
Amadesi S, Gatti M, Rinaldi M, Pea F, Viale P, Gaibani P. Amadesi S, et al. Among authors: gaibani p. Int J Antimicrob Agents. 2024 Apr;63(4):107107. doi: 10.1016/j.ijantimicag.2024.107107. Epub 2024 Feb 6. Int J Antimicrob Agents. 2024. PMID: 38325723 No abstract available.
Performance evaluation of Bruker UMIC® microdilution panel and disc diffusion to determine cefiderocol susceptibility in Enterobacterales, Acinetobacter baumannii, Pseudomonas aeruginosa, Stenotrophomonas maltophilia, Achromobacter xylosoxidans and Burkolderia species.
Bianco G, Boattini M, Comini S, Gaibani P, Cavallo R, Costa C. Bianco G, et al. Among authors: gaibani p. Eur J Clin Microbiol Infect Dis. 2024 Mar;43(3):559-566. doi: 10.1007/s10096-024-04745-7. Epub 2024 Jan 19. Eur J Clin Microbiol Infect Dis. 2024. PMID: 38240988
Could an optimized joint pharmacokinetic/pharmacodynamic target attainment of continuous infusion ceftazidime-avibactam be a way to avoid the need for combo therapy in the targeted treatment of deep-seated DTR Gram-negative infections?
Gatti M, Rinaldi M, Bonazzetti C, Gaibani P, Giannella M, Viale P, Pea F. Gatti M, et al. Among authors: gaibani p. Antimicrob Agents Chemother. 2023 Nov 15;67(11):e0096923. doi: 10.1128/aac.00969-23. Epub 2023 Oct 16. Antimicrob Agents Chemother. 2023. PMID: 37843260 Free PMC article.
A descriptive pharmacokinetic/pharmacodynamic analysis of continuous infusion meropenem/vaborbactam in the treatment of critically ill patients with documented KPC-producing Klebsiella pneumoniae ventilator-associated pneumonia.
Gatti M, Rinaldi M, Gaibani P, Siniscalchi A, Tonetti T, Viale P, Pea F. Gatti M, et al. Among authors: gaibani p. Int J Antimicrob Agents. 2023 Nov;62(5):106992. doi: 10.1016/j.ijantimicag.2023.106992. Epub 2023 Sep 29. Int J Antimicrob Agents. 2023. PMID: 37778429 No abstract available.
109 results